MoonLake Immunotherapeutics
NASDAQ:MLTXBiotechnology
+$0.13 today
- Market cap
- $918.30M
- Beta
- 1.04
- P/E (TTM)
- -5.4
- EPS (TTM)
- -$3.61
Volume 1.32M
Average 0.99M
MLTX Financing Cash Flow
Net cash exchanged with lenders and shareholders through borrowing, repayments, buybacks, and dividends.
MoonLake ImmunotherapeuticsNASDAQ: MLTX
Financing Cash Flow · Q1 FY2026 · quarter ended Mar 2026
Financing cash flow dips below year-ago levels
Q1 FY2026 financing cash flow of $30.64M fell 58.1% year over year, behind the +40.9% change in trailing-twelve-month financing cash flow. Sequentially, it fell 57.7% from the prior quarter. Over 3 fiscal years it compounded at +6.8% a year.
Context
- Financing cash flow increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from -58.1% toward the trailing-twelve-month pace of +40.9%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Financing Cash Flow history
USD · from the cash flow
- Latest · FY2025
- 146M USD
- Year-over-year change
- +184.5%
- 4-year CAGR
- +35.5%
| Period | Period end | Financing Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 146M | +184.5% |
| FY2024 | 2024-12-31 | 51.31M | -89.3% |
| FY2023 | 2023-12-31 | 479.7M | +300.8% |
| FY2022 | 2022-12-31 | 119.69M | +176.7% |
| FY2021 | 2021-12-31 | 43.26M | — |
Financing Cash Flow vs competitors
How MLTX compares with its peers on the latest reported figures
- MLTX's LTM Mar 2026 financing cash flow of $103.52M is the 7th largest of the 11 companies compared; the peer median is $134.89M.
- Its year-over-year change of +40.9% is the 7th highest of 11, against a peer median of +62.3%.
- Over three fiscal years its annual growth of +6.8% compares with a peer median of +26.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $1.03B | +2428.7% | +42.6% | 54053.9% | |
ORKAOruka Therapeutics, Inc. | LTM Sep 2026 | $830.71M | +390.1% | — | — |
ALMSAlumis Inc. Common Stock | LTM Jun 2026 | $360.93M | +53.0% | -72.7% | 4878.8% |
| LTM Aug 2026 | $261.21M | +28.6% | +26.8% | 37.2% | |
| FY2025 | $142.01M | +71.6% | — | 10519.4% | |
ZURAZura Bio Limited | LTM Mar 2026 | $127.78M | +11.1% | — | — |
| LTM Mar 2026 | $103.52M | +40.9% | +6.8% | — | |
| LTM Mar 2026 | $102.81M | -191.7% | — | 44.2% | |
| LTM Mar 2026 | $65.68M | +25657.6% | — | — | |
| LTM Mar 2026 | $52.19M | -29.8% | — | 623.8% | |
| FY2025 | $1.09M | +381.5% | — | 1707.8% | |
| Peer median (excluding MLTX) | $134.89M | +62.3% | +26.8% | 1707.8% | |
Competitors are the stored peer set for MLTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (53.64M) | (49.97M) | (44.08M) | (121.24M) | (229.1M) |
| Depreciation & Amortization | 4.97K | 12.36K | 13.16K | 1.38M | 2.62M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 10.86M | 9.65M | 7.11M | 7.28M | 12.9M |
| Change in Working Capital | 4.48M | (1.43M) | (6.22M) | (3.78M) | 19.88M |
| Accounts Receivables | (148.77K) | (68.36K) | (840K) | (1.79M) | (2.03M) |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 1.57M | (1.31M) | 0 | 0 | 0 |
| Other Working Capital | 3.06M | (44.8K) | (6.22M) | (2M) | 21.9M |
| Other Non-Cash Items | 13.98M | (4.51M) | 399.51K | (225.71K) | (2.3M) |
| Operating Cash Flow | (35.18M) | (55.89M) | (42.78M) | (116.59M) | (196.01M) |
| Capital Expenditures | (50.71K) | (16.01K) | (284.63K) | (519.52K) | (35K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | (42.23M) | (175.73M) | (350.28M) | (265.37M) |
| Sales of Investments | 0 | 9.9M | 150.83M | 145.2M | 468.4M |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (50.71K) | (32.34M) | (25.18M) | (205.6M) | 202.99M |
| Debt Repayment | 15M | (15M) | 0 | 0 | 73.02M |
| Common Stock Issued | 28.27M | 3.79K | 482.45M | 52.54M | 72.98M |
| Common Stock Repurchased | (6.2K) | 0 | 0 | (50) | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | 134.69M | (2.75M) | (1.23M) | 0 |
| Financing Cash Flow | 43.26M | 119.69M | 479.7M | 51.31M | 146M |
| Effect of Forex Changes | (1.33M) | 8.54K | (75.31K) | 127.97K | 1.11M |
| Net Change in Cash | 6.7M | 31.47M | 411.66M | (270.74M) | 154.09M |
| Free Cash Flow | (35.23M) | (55.91M) | (43.06M) | (117.11M) | (196.04M) |
MoonLake Immunotherapeutics
NASDAQ:MLTX
Intrinsic Alpha fair value
Locked
Current Price
$10.79
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.